AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but ...

Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S.

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

Merck (NYSE:MRK) and Daiichi Sankyo (OTCPK:DSNKY) (OTCPK:DSKYF) announced Thursday the voluntary withdrawal of their U.S. marketing application targeted at the FDA’s accelerated approval of the lung ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.

Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...